Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis
Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms...
Gespeichert in:
| Veröffentlicht in: | Case reports in dermatology Jg. 17; H. 1; S. 128 - 136 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
S. Karger AG
28.03.2025
Karger Publishers |
| Schlagworte: | |
| ISSN: | 1662-6567, 1662-6567 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin. Patient Presentation: A woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration. Conclusion: Dalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives – 257 h for dalbavancin and 195 h for oritavancin – allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin. |
|---|---|
| AbstractList | Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin. Patient Presentation: A woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration. Conclusion: Dalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives – 257 h for dalbavancin and 195 h for oritavancin – allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin. Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin. A woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration. Dalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives - 257 h for dalbavancin and 195 h for oritavancin - allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin. Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin.IntroductionDalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin.A woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration.Patient PresentationA woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration.Dalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives - 257 h for dalbavancin and 195 h for oritavancin - allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin.ConclusionDalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives - 257 h for dalbavancin and 195 h for oritavancin - allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin. |
| Author | Bai, Jina Preciado, Emily Frech Harlow, Mary Baxter Blank, Nina |
| Author_xml | – sequence: 1 givenname: Jina surname: Bai fullname: Bai, Jina – sequence: 2 givenname: Emily Frech surname: Preciado fullname: Preciado, Emily Frech – sequence: 3 givenname: Mary Baxter surname: Harlow fullname: Harlow, Mary Baxter – sequence: 4 givenname: Nina surname: Blank fullname: Blank, Nina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40303649$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUstuGyEUHVWpmke76A9Us2wXbmB4DasqStI2UqRUfazRHWBsIgZcwIn8Hf3hYjuxkqorDpdzzwHOPW4OQgy2ad5i9BFjJk8RQowywuSL5ghz3s044-LgCT5sjnO-RYhLxsmr5pAiggin8qj5c5FW8_a7BV1cDO29K4v2MmYX4nLhvIMWgml_rHOxk9MVTMsSp1xBMClOth2j9_HehXl7AX6AOwjahW3TTXLlcX9mJhdcLgm2LhtG-61iG8rO8qYaxGltvSsuv25ejuCzffOwnjS_Pl_-PP86u775cnV-dj3TlNIy6xlHAnPbSykwkEGCQVZoZLAhmnRM9liDxVIy0fWSEGQkHYWV1pgB2wGTk-Zqp2si3KplchOktYrg1LYQ01xBKk57qzgBrnuEh1EwOhotKYO-q4ZMSKhfX7U-7bSWq2GyRteXJfDPRJ-fBLdQ83incIe2aVSF9w8KKf5e2VzU5LK23kOwcZUVwVJwhgTtKvXdU7O9y2OslfBhR9Ap5pzsuKdgpDYjo_YjU7mn_3B1DW6TU72n8__p-AsA-8Th |
| CitedBy_id | crossref_primary_10_1007_s40278_025_83397_y |
| Cites_doi | 10.1016/j.jaad.2017.05.041 10.1016/j.jaad.2023.02.073 10.1080/14740338.2022.2122437 10.1086/379015 10.1016/j.ijantimicag.2024.107165 10.1016/j.jaip.2018.08.013 10.1093/ofid/ofy331 10.1111/bjd.12501 10.1016/j.alit.2019.03.006 10.3390/pharmacy8020070 10.1016/j.jaad.2023.02.072 10.1310/hpj4909-851 10.2147/TCRM.S271445 |
| ContentType | Journal Article |
| Copyright | 2025 The Author(s). Published by S. Karger AG, Basel. 2025 The Author(s). Published by S. Karger AG, Basel 2025 |
| Copyright_xml | – notice: 2025 The Author(s). Published by S. Karger AG, Basel. – notice: 2025 The Author(s). Published by S. Karger AG, Basel 2025 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1159/000545359 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | DRESS Syndrome from Dalbavancin and Oritavancin |
| EISSN | 1662-6567 |
| EndPage | 136 |
| ExternalDocumentID | oai_doaj_org_article_63a6c801bf754fdc945a82ad0579a453 PMC12040303 40303649 10_1159_000545359 |
| Genre | Journal Article Case Reports |
| GroupedDBID | --- 0~B 3O. 4.4 53G 5VS 6J9 7X7 8FI 8FJ AAYXX ABBTS ABDBF ABPAZ ABUWG ABWCG ACGFS ACUHS ADBBV AEGXH AEYAO AFKRA AHFRZ AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CYUIP DIK E0A EBS F5P FB. FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR ITC KQ8 M-- M48 M~E O5R O5S OK1 PHGZM PQQKQ PROAC RNS RPM TR2 UKHRP ADRAZ ALIPV C1A CAG COF EJD IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c444t-8560716e89971a3b9ad0e7c0d1d3c325981cae19957289330d94f7e9eddb1eb13 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001478917400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1662-6567 |
| IngestDate | Fri Oct 03 12:37:24 EDT 2025 Tue Sep 30 17:03:35 EDT 2025 Fri Oct 03 00:10:28 EDT 2025 Fri May 02 01:43:13 EDT 2025 Tue Nov 18 22:34:03 EST 2025 Sat Nov 29 07:59:33 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Drug eruption Infections Adverse drug reaction |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc/4.0 2025 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c444t-8560716e89971a3b9ad0e7c0d1d3c325981cae19957289330d94f7e9eddb1eb13 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://doaj.org/article/63a6c801bf754fdc945a82ad0579a453 |
| PMID | 40303649 |
| PQID | 3197650742 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_63a6c801bf754fdc945a82ad0579a453 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12040303 proquest_miscellaneous_3197650742 pubmed_primary_40303649 crossref_primary_10_1159_000545359 crossref_citationtrail_10_1159_000545359 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-28 |
| PublicationDateYYYYMMDD | 2025-03-28 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel, Switzerland |
| PublicationTitle | Case reports in dermatology |
| PublicationTitleAlternate | Case Rep Dermatol |
| PublicationYear | 2025 |
| Publisher | S. Karger AG Karger Publishers |
| Publisher_xml | – name: S. Karger AG – name: Karger Publishers |
| References | ref13 ref12 ref11 ref10 ref2 ref1 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref9 doi: 10.1016/j.jaad.2017.05.041 – ident: ref3 doi: 10.1016/j.jaad.2023.02.073 – ident: ref6 doi: 10.1080/14740338.2022.2122437 – ident: ref5 doi: 10.1086/379015 – ident: ref13 doi: 10.1016/j.ijantimicag.2024.107165 – ident: ref1 doi: 10.1016/j.jaip.2018.08.013 – ident: ref7 doi: 10.1093/ofid/ofy331 – ident: ref4 doi: 10.1111/bjd.12501 – ident: ref12 doi: 10.1016/j.alit.2019.03.006 – ident: ref10 doi: 10.3390/pharmacy8020070 – ident: ref2 doi: 10.1016/j.jaad.2023.02.072 – ident: ref11 doi: 10.1310/hpj4909-851 – ident: ref8 doi: 10.2147/TCRM.S271445 |
| SSID | ssj0069563 |
| Score | 2.3144054 |
| Snippet | Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including... Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant (MRSA). To... Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 128 |
| SubjectTerms | Single Case |
| Title | Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40303649 https://www.proquest.com/docview/3197650742 https://pubmed.ncbi.nlm.nih.gov/PMC12040303 https://doaj.org/article/63a6c801bf754fdc945a82ad0579a453 |
| Volume | 17 |
| WOSCitedRecordID | wos001478917400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1662-6567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069563 issn: 1662-6567 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1662-6567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069563 issn: 1662-6567 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVKGR databaseName: Karger Open Access customDbUrl: eissn: 1662-6567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069563 issn: 1662-6567 databaseCode: M-- dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.karger.com/OpenAccess providerName: Karger AG – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1662-6567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069563 issn: 1662-6567 databaseCode: 7X7 dateStart: 20170101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1662-6567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069563 issn: 1662-6567 databaseCode: BENPR dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jj9MwFH6CASEuiJ2yVAZx4BKR2E5sHxmmIy7TqUYg9RY5XqDSNKm6zIgLf4I_zLOdVi0aiQsXy4mfZct-fouX7wG8V6VTXDueMV-GEGasQTnoPa74XHtBTemVjcEmxHgsp1M12Qv1Fe6EJXjgNHAfK6Yrg2K08aLk3hrFSy2ptuERpeZlxPnMhdo6U0kGV2j1sx5HCPV1jFyHtAGQdE_7RJD-myzLvy9I7mmc04fwoDcVyafUxUdwy7WP4d5Zfxj-BH6fLDffyYVLTxNI2FElow59_24Rdkk00a0lCZF8ZjAzX6y7-QozCaOAeGSB7hpVFznRl40OdwFmbax0HnYM-u9DdF0SKMgkgbGmJs-xgW7-04V7dKun8O109PXzl6yPsZAZzvk6k2UAmKscul2i0KxROLJOmNwWlhmGvpEsjHbhHbdA14yx3CruhVPO2qZAOc-ewVHbte4FECzgtCkqTXGwOc2VbYSR1kuvjZQNH8CH7djXpgcgD3EwLuvoiJSq3k3TAN7tSBcJdeMmouMwgTuCAJQdfyD71D371P9inwG83U5_jQsrnJbo1nWbVY2ySaD5KjgdwPPEDrumeB40P8cuyANGOejLYUk7-xHBuwuax9ov_0fvX8F9GuIR5yyj8jUcrZcb9wbumiuc8OUQboupiKkcwp3j0XhyMYzLBNOzX6M_aIIYzA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drug+Reaction+with+Eosinophilia+and+Systemic+Symptoms+Syndrome+following+Dalbavancin+and+Oritavancin+Administration+in+a+Patient+with+Osteomyelitis&rft.jtitle=Case+reports+in+dermatology&rft.au=Jina+Bai&rft.au=Emily+Frech+Preciado&rft.au=Mary+Baxter+Harlow&rft.au=Nina+Blank&rft.date=2025-03-28&rft.pub=Karger+Publishers&rft.eissn=1662-6567&rft.volume=17&rft.issue=1&rft.spage=128&rft.epage=136&rft_id=info:doi/10.1159%2F000545359&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_63a6c801bf754fdc945a82ad0579a453 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-6567&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-6567&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-6567&client=summon |